Home > Insider Trading > Filing (0001140361-15-029336)

Filing Details

Accession Number:: 0001140361-15-029336
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2015-07-31 16:21:58
Reporting Period:: 2015-07-29

Filing Date:: 2015-07-31
Accepted Time:: 2015-07-31 16:21:58
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1302573	Oncomed Pharmaceuticals Inc	OMED	Pharmaceutical Preparations (2834)	383572512

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1553353	Austin Gurney	C/O Oncomed Pharmaceuticals, Inc. 800 Chesapeake Drive Redwood City CA 94063	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2015-07-29	7,000	$20.68	56,419	No	4	S	Direct
Common Stock	Disposition	2015-07-30	5,901	$21.01	50,518	No	4	S	Direct
Common Stock	Disposition	2015-07-30	1,099	$21.47	49,419	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 29, 2015.
This transaction was executed in multiple trades in prices ranging from $20.28 to $21.095, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit.
This transaction was executed in multiple trades in prices ranging from $20.40 to $21.37, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
This transaction was executed in multiple trades in prices ranging from $21.41 to $21.51, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.